What Is AICAR? AMPK Activator Profile

Cover illustration: AI-generated editorial artwork. Conceptual only; not an exact molecular structure, actual laboratory result or evidence of clinical effects.

AICAR — 5-aminoimidazole-4-carboxamide ribonucleoside — is a nucleoside, not a peptide. Its research role is as a pharmacological activator of AMPK, and the way it achieves that is indirect enough to be worth understanding properly, because the indirection is also the source of its main limitation.

For laboratory research use only. The research materials supplied by HealthyWelness are not approved medicines, foods or cosmetics and are not for human or veterinary use. This article summarises published research and is not medical advice.

Key points

Class: nucleoside; an intermediate in purine biosynthesis.
Active species: ZMP, formed inside the cell by phosphorylation of AICAR.
Mechanism: ZMP mimics AMP, and AMPK responds to AMP.
Key limitation: ZMP affects other AMP-sensitive enzymes, so AICAR is not an AMPK-specific tool.
Literature: very large, spread across many tissues and models.

The two-step mechanism

Step	What happens	Consequence
1. Uptake	AICAR enters the cell via nucleoside transporters	Transporter expression determines which cells respond
2. Phosphorylation	Adenosine kinase converts AICAR to ZMP	ZMP, not AICAR, is the active species
3. AMPK activation	ZMP binds AMPK at AMP-binding sites	The kinase behaves as though AMP has risen

The elegance of this is that it uncouples the AMPK signal from actual energy status. Ordinarily, activating AMPK means depleting ATP, which changes a great deal besides AMPK. AICAR produces the AMP-like signal while ATP remains normal, isolating the kinase’s contribution.

Two practical implications follow immediately. Cells lacking adequate nucleoside transport or adenosine kinase activity will not convert AICAR, so a negative result may reflect the conversion step rather than AMPK biology. And cell-free assays require ZMP, not AICAR, since there is nothing present to do the conversion.

Why AMPK is studied so widely

AMPK is a heterotrimeric kinase that functions as a cellular energy sensor. When the AMP to ATP ratio rises, it is activated and shifts metabolism toward ATP-generating processes while suppressing ATP-consuming ones. It also intersects with autophagy and mitophagy regulation, and with mTOR signalling.

Because every cell manages energy, AMPK is everywhere, and a pharmacological activator has accordingly been tested nearly everywhere:

Study	Model	Reported finding
Chandrasekaran et al., 2024	Diabetic polyneuropathy	Prevention and reversal in the model, attributed to mitophagy regulation
Tsogbadrakh et al., 2019	Cisplatin-induced acute kidney injury	Protection, with a JAK/STAT/SOCS pathway account
Kim et al., 2008	Osteoblasts, palmitate challenge	Inhibition of palmitate-induced apoptosis

Published work also covers alcohol-related fatty liver in rats and myocardial injury in hemorrhagic shock models. The breadth is real, and it is exactly what one would predict for a tool acting on a ubiquitous kinase.

The specificity problem, stated plainly

ZMP is an AMP analogue. AMPK is not the only AMP-sensitive protein in a cell: AMP regulates enzymes in glycogen metabolism and in glucose handling, among others. So when ZMP accumulates, AMPK is affected and so, potentially, is anything else that reads AMP.

This means “AICAR produced effect X, therefore AMPK causes X” is not a valid inference on its own. The controls that make the inference sound are the ones to look for when reading a paper:

AMPK knockout, knockdown, or a dominant-negative construct, showing the effect disappears.
A structurally unrelated AMPK activator reproducing the effect.
Direct measurement of AMPK activation, such as phosphorylation of a known substrate, in the same system.

Many good papers include these; some do not. The distinction is the single most useful thing to check in this literature.

Handling in the lab

Consideration	Practice
Form	Powder; store sealed and desiccated at −20 °C, protected from light
Solubility	Water-soluble as a nucleoside; warming and gentle agitation help at higher concentrations
Stock solutions	Aliquot; prepare working dilutions fresh in medium
Cell-free work	Use ZMP, not AICAR — no conversion will occur
Identity check	LC-MS; peptide methods are not applicable

Because this is a nucleoside rather than a peptide, bacteriostatic water and peptide reconstitution tables are not relevant. Work from the molecular weight on the certificate of analysis; our calculator covers the peptides in a mixed study set.

Our AICAR research material is supplied for laboratory research use. Certificates are available for listed products — contact us for the latest report.

Open questions

How large are the off-target AMP-mimetic effects at concentrations commonly used in cell work?
How much does variation in nucleoside transport and adenosine kinase activity explain differences between cell types?
Which of the published tissue-protective findings hold up with AMPK-dependence controls?

Frequently asked questions

What is AICAR?

AICAR is 5-aminoimidazole-4-carboxamide ribonucleoside, a nucleoside and an intermediate in purine biosynthesis. It is not a peptide. In research it is used as a pharmacological activator of AMP-activated protein kinase.

How does AICAR activate AMPK?

AICAR is taken up by cells and phosphorylated to ZMP, which is an analogue of AMP. AMPK is activated by rising AMP levels, so accumulating ZMP mimics the signal of low cellular energy charge without the cell actually being energy-depleted.

Is AICAR specific for AMPK?

No, and this is its principal limitation. ZMP is an AMP mimetic, so it can affect other AMP-sensitive enzymes, including those in glycogen and glucose metabolism. Effects observed with AICAR should not be attributed to AMPK without additional evidence.

Is AICAR a peptide?

No. It is a small nucleoside molecule. It is catalogued alongside research peptides but shares none of their handling characteristics.

Why does AICAR appear in so many different disease models?

AMPK sits at the centre of cellular energy regulation and is expressed in essentially all tissues, so a pharmacological activator has been tested across kidney, nerve, bone, liver, heart and other models.

References

Chandrasekaran K, et al. Administration of AICAR, an AMPK Activator, Prevents and Reverses Diabetic Polyneuropathy (DPN) by Regulating Mitophagy. Int J Mol Sci. 2024. PMID: 39795939 https://pubmed.ncbi.nlm.nih.gov/39795939/
Tsogbadrakh B, et al. AICAR, an AMPK activator, protects against cisplatin-induced acute kidney injury through the JAK/STAT/SOCS pathway. Biochem Biophys Res Commun. 2019. PMID: 30616891 https://pubmed.ncbi.nlm.nih.gov/30616891/
Kim JE, et al. AMPK activator, AICAR, inhibits palmitate-induced apoptosis in osteoblast. Bone. 2008. PMID: 18502715 https://pubmed.ncbi.nlm.nih.gov/18502715/